Bulletin from the extraordinary general meeting of Xspray Pharma AB (publ)
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Small Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
The following resolutions were passed at the extraordinary general meeting (the “EGM”) of Xspray Pharma AB (publ) (“Xspray”) on 25 May 2023.
Authorisation to issue new shares with deviation from the shareholders’ preferential rights
The EGM resolved, in accordance with the board of directors’ proposal, to authorise the board of directors, at one or several occasions and for the period until the next annual general meeting, with deviation from the shareholders’ preferential rights, to increase the company’s share capital by issuing new shares, warrants and/or convertibles. Such share issue resolution may be made with or without provisions for contribution in kind or set-off or other conditions. The authorisation may only be utilised to the extent that the number of shares issued by virtue of the authorisation corresponds to not more than 20 per cent of the total number of shares outstanding at the time of the general meeting’s resolution on the proposed authorisation.
The authorisation replaces the authorisation for the board of directors to resolve on issuances of new shares with deviation from the shareholders’ preferential rights as proposed to the company’s annual general meeting on 16 May 2023.
Authorisation to issue new shares without deviation from the shareholders’ preferential rights
The EGM resolved, in accordance with the board of directors’ proposal, to authorise the board of directors, at one or several occasions and for the period until the next annual general meeting, without deviation from the shareholders’ preferential rights, to increase the company’s share capital by issuing new shares, warrants and/or convertibles. Such share issue resolution may be made with or without provisions for contribution in kind or set-off or other conditions.